GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Treace Medical Concepts Inc (NAS:TMCI) » Definitions » EBITDA per Share

Treace Medical Concepts (Treace Medical Concepts) EBITDA per Share : $-0.70 (TTM As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Treace Medical Concepts EBITDA per Share?

Treace Medical Concepts's EBITDA per Share for the three months ended in Mar. 2024 was $-0.25. Its EBITDA per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.70.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per Share growth rate using EBITDA per Share data.

The historical rank and industry rank for Treace Medical Concepts's EBITDA per Share or its related term are showing as below:

During the past 5 years, the highest 3-Year average EBITDA per Share Growth Rate of Treace Medical Concepts was -121.90% per year. The lowest was -121.90% per year. And the median was -121.90% per year.

TMCI's 3-Year EBITDA Growth Rate is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 7.9
* Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.

Treace Medical Concepts's EBITDA for the three months ended in Mar. 2024 was $-15.5 Mil.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 5 years, the highest 3-Year average EBITDA Growth Rate of Treace Medical Concepts was -139.80% per year. The lowest was -139.80% per year. And the median was -139.80% per year.


Treace Medical Concepts EBITDA per Share Historical Data

The historical data trend for Treace Medical Concepts's EBITDA per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Treace Medical Concepts EBITDA per Share Chart

Treace Medical Concepts Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA per Share
-0.06 0.05 -0.33 -0.66 -0.64

Treace Medical Concepts Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBITDA per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.19 -0.16 -0.24 -0.05 -0.25

Treace Medical Concepts EBITDA per Share Calculation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Treace Medical Concepts's EBITDA per Share for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA per Share(A: Dec. 2023 )
=EBITDA/Shares Outstanding (Diluted Average)
=-39.008/60.852
=-0.64

Treace Medical Concepts's EBITDA per Share for the quarter that ended in Mar. 2024 is calculated as

EBITDA per Share(Q: Mar. 2024 )
=EBITDA/Shares Outstanding (Diluted Average)
=-15.45/61.793
=-0.25

EBITDA per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.70

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Treace Medical Concepts  (NAS:TMCI) EBITDA per Share Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals EBIT. EBIT is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost, it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies.


Treace Medical Concepts EBITDA per Share Related Terms

Thank you for viewing the detailed overview of Treace Medical Concepts's EBITDA per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Treace Medical Concepts (Treace Medical Concepts) Business Description

Traded in Other Exchanges
N/A
Address
100 Palmetto Park Place, Ponte Vedra, FL, USA, 32081
Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The Company operates and manages its business as one segment, which is the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers, and hospitals.
Executives
F Barry Bays director
Betsy Hanna director C/O TREACE MEDICAL CONCEPTS, INC., 203 FORT WADE RD #150, PONTE VEDRA BEACH FL 32081
Deepti Jain director 3701 WAYZATA BLVD, MINNEAPOLIS MN 55416
Sean F. Scanlan officer: See Remarks C/O TREACE MEDICAL CONCEPTS, INC., 203 FORT WADE ROAD, SUITE 150, PONTE VEDRA FL 32081
James T Treace director 117 BRISTOL PLACE, PONTE VEDRA BEACH FL 32082
Richard W Mott director 1221 CROSSMAN AVENUE, SUNNYVALE CA 94089
Thomas E Timbie director
Daniel E. Owens officer: Chief HR Officer C/O TREACE MEDICAL CONCEPTS, INC., 203 FORT WADE ROAD, SUITE 150, PONTE VEDRA FL 32081
Scot Michael Elder officer: *See "Remarks" C/O TREACE MEDICAL CONCEPTS, INC., 203 FORT WADE ROAD, SUITE 150, PONTE VEDRA FL 32081
Mark Hair officer: Chief Financial Officer C/O RESTORATION ROBOTICS, INC., 128 BAYTECH DRIVE, SAN JOSE CA 95134
Aaron Berutti officer: Sr. VP, Sales C/O TREACE MEDICAL CONCEPTS, INC., 203 FORT WADE ROAD, SUITE 150, PONTE VEDRA FL 32081
John T. Treace director, 10 percent owner, officer: Chief Executive Officer C/O TREACE MEDICAL CONCEPTS, INC., 203 FORT WADE ROAD, SUITE 150, PONTE VEDRA FL 32081
Lance A Berry director 5677 AIRLINE ROAD, ARLINGTON TN 38002
Jane E Kiernan director 525 W ROSCOE, CHICAGO IL 60657
John R Treace director 5677 AIRLINE RD, ARLINGTON VA 38002

Treace Medical Concepts (Treace Medical Concepts) Headlines

From GuruFocus

Treace Medical Concepts, Inc. Announces Proposed Public Offering of Common Stock

By Stock market mentor Stock market mentor 02-07-2023

Treace to Report First Quarter 2023 Financial Results on May 8, 2023

By sperokesalga sperokesalga 04-20-2023